한글목차

세계 암 면역 임상시험 시장 규모는 2033년까지 11.3%의 CAGR을 나타낼 것으로 예상됩니다.

새로운 약물이나 의료기술의 개입을 평가하는 임상시험을 중재시험이라고 합니다. 암 면역 임상시험은 암에 대한 새로운 면역 요법의 효과를 평가합니다. 중재적 영상의학과 전문의들은 종양 내 소작술과 대체 경동맥 간내 치료의 새로운 기법과 장비를 개발하여 환자들의 치료 성적을 지속적으로 향상시키고 있습니다. 또한, 중재적 방사선과 전문의는 면역증강 치료를 통해 절제술(방사선 및 마이크로파 소작술), 색전술 등 면역치료의 역할을 강화하고 있습니다.

2023년 1월 현재 중재적 암 면역치료 임상시험은 7,000건 이상입니다. 이 중 3,000건 이상이 임상 3상 시험입니다. 흑색종, 비소세포폐암, 대장암은 암 면역 임상시험에서 가장 많이 연구되는 암종입니다. 체크포인트 억제제, CAR T세포, 종양 용해성 바이러스는 암 면역 임상시험에서 가장 많이 검토되는 면역 요법입니다.

본 보고서는 세계의 암 면역 임상시험 시장을 조사했으며, 시장 개요, 시장 성장에 영향을 미치는 각종 영향요인 분석, 시장 규모 추이 및 예측, 각 부문별/지역별/주요 국가별 분석, 경쟁 환경, 주요 기업 프로파일 등의 정보를 정리하여 전해드립니다.

목차

제1장 보고서 개요

제2장 주요 요약

제3장 시장 개요

• 주요 조사 결과
• 시장 역학
  • 시장 성장 촉진요인
  • 시장 성장 억제요인
  • 시장 기회
• Porter의 Five Forces 분석
• PEST 분석
• COVID-19의 영향 분석

제4장 암 면역 임상시험 시장 분석 : 단계별

• 주요 조사 결과
• 시장의 매력 지수
• 시장 규모 추산 및 예측
• 단계 I
• 단계 II
• 단계Ⅲ
• 단계 IV

제5장 암 면역 임상시험 시장 분석 : 설계별

• 주요 조사 결과
• 시장의 매력 지수
• 시장 규모 추산 및 예측
• 중재적 시험
• 관찰 시험
• 확장 참가 시험

제6장 암 면역 임상시험 시장 분석 : 적응증별

• 주요 조사 결과
• 시장의 매력 지수
• 시장 규모 추산 및 예측
• 고형 종양
• 혈액암

제7장 암 면역 임상시험 시장 분석 : 지역별

• 주요 조사 결과
• 시장 규모 추이와 예측

제8장 북미의 암 면역 임상시험 시장 분석

제9장 유럽의 암 면역 임상시험 시장 분석

제10장 아시아태평양의 암 면역 임상시험 시장 분석

제11장 라틴아메리카의 암 면역 임상시험 시장 분석

제12장 중동 및 아프리카의 암 면역 임상시험 시장 분석

제13장 기업 개요

• 경쟁 구도
• 전략적 전망
• Merck &Co., Inc.
• Bristol-Myers Squibb Company
• Medpace, Inc.
• Novartis AG
• AstraZeneca plc
• BioNTech SE
• Exscientia plc
• F. Hoffmann-La Roche AG
• Pfizer Inc.
• Syneos Health
• IO Biotech, Inc.
• ICON plc
• IQVIA Inc.

제14장 결론 및 제안

영문목차

The global Immuno-Oncology Clinical Trials market is projected to grow at a CAGR of 11.3% by 2033.

“The Immuno-Oncology Clinical Trials Market Report 2023-2033”: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to understand the industry and its underlying dynamics better. It will be useful for companies that want to expand into different industries or their existing operations in a new region.

Increasing Number of Interventional Immuno Oncology Clinical Trials Driving Market Growth

Clinical studies that evaluate a new intervention, like a medicine or a medical technology, are known as interventional trials. Clinical trials in immuno oncology evaluate the efficacy of brand-new immunotherapies for cancer. Furthermore, interventional radiologists have created new procedures and equipment for both intratumor ablative techniques to cure disease and a variety of transarterial intrahepatic therapeutic alternatives, continually improving patient results. Interventional radiologists undertake treatments that can result in immune augmentation, strengthening the role of immunotherapies, such as ablative (radiofrequency and microwave ablation) or embolic.

The number of interventional immuno oncology clinical trials was over 7,000 as of January 2023. More than 3,000 of these trials fell under Phase III. Melanoma, NSCLC, and colorectal cancer are the cancer types that are examined in immuno oncology clinical trials the most frequently. Checkpoint inhibitors, CAR T cells, and oncolytic viruses are the immunotherapies most frequently investigated in immuno oncology clinical trials.

Serious Issues and Substantial Medical Costs Likely to Challenge Industry Growth

Immunotherapy is a relatively recent type of cancer treatment using the body's immune system to combat cancer cells. Although it is expensive, it has shown significant potential in treating several tumors. There are a few factors that contribute to immunotherapy's high cost. It is a complicated treatment that necessitates much research and development. Second, it is frequently produced using pricey biologic medications that are challenging to produce. Third, immunotherapy is in high demand, which raises the cost. Many cancer patients may find it difficult to get immunotherapy due to its high cost. Immunotherapy, for instance, typically costs more than $100,000 a year in the United States.

Further, high medical costs are a big issue for patients worldwide. There is intense pressure to reduce costs and demonstrate value. The lack of accessible drugs has impacted population health in underdeveloped nations and shortened average life expectancy. Immunotherapy often involves an average annual cost of above $100,000 per patient; if the worth of medical insurance were considered, this cost would rise to $850,000 per patient. As a result of the high price of immuno oncology therapy, it is projected that the market for immuno oncology medications will expand slowly.

What Questions Should You Ask Before Buying a Market Research Report?

• How is immuno oncology clinical trials market evolving?
• What is driving and restraining immuno oncology clinical trials market?
• How will each immuno oncology clinical trials submarket segment grow over the forecast period, and how much revenue will these submarkets account for in 2033?
• How will the market shares for each immuno oncology clinical trials submarket develop from 2023 to 2033?
• What will be the main driver for the overall market from 2023 to 2033?
• Will leading immuno oncology clinical trials markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2033, and which geographical region will lead the market in 2033?
• Who are the leading players, and what are their prospects over the forecast period?
• What are the immuno oncology clinical trials projects for these leading companies?
• How will the industry evolve during the period between 2023 and 2033? What are the implications of immuno oncology clinical trials projects taking place now and over the next 10 years?
• Is there a greater need for product commercialization to further scale immuno oncology clinical trials market?
• Where is the immuno oncology clinical trials market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Immuno Oncology Clinical Trials market today, and over the next 10 years:

• Our 249-page report provides 96 tables and 145 charts/graphs exclusively to you
• The report highlights key lucrative areas in the industry so you can target them - NOW
• It contains in-depth analysis of global, regional and national sales and growth
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the immuno oncology clinical trials market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2033 and other analyses reveal commercial prospects

• In addition to revenue forecasting to 2033, our new study provides you with recent results, growth rates, and market shares
• You will find original analyses, with business outlooks and developments
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising Immuno Oncology Clinical Trials prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, ""V" ", "L", "W" and "U" are discussed in this report.

Segments Covered in the Report:

Phase

• Phase I
• Phase II
• Phase III
• Phase IV

Design

• Interventional Trials
• Observational Trials
• Expanded Access Trials

Indication

• Solid Tumours
• Hematological Cancer

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 20 leading national markets:

North America

• U.S
• Canada

Europe

• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia Pacific

Latin America

• Brazil
• Mexico
• Rest of Latin America

MEA

• GCC
• South Africa
• Rest of MEA

The report also includes profiles and for some of the leading companies in the Immuno Oncology Clinical Trials Market, 2023 to 2033, with a focus on this segment of these companies' operations.

Leading Companies and the Potential for market growth:

Overall world revenue for Immuno Oncology Clinical Trials Market, 2023 to 2033 in terms of value the market will surpass US$6,800 million in 2023, our work calculates. We predict strong revenue growth through to 2033. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Immuno Oncology Clinical Trials Market, 2023 to 2033 report help you?

In summary, our 240+ page report provides you with the following knowledge:

• Revenue forecasts to 2033 for Immuno Oncology Clinical Trials Market 2023 to 2033, with forecasts for phase, design, and indication, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
• Revenue forecasts to 2033 for five regional and 20 key national markets - See forecasts for the Immuno Oncology Clinical Trials Market, 2023 to 2033 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market - including company profiles for Merck & Co., Inc., Bristol-Myers Squibb Company, Novartis AG, AstraZeneca plc, and F. Hoffmann-La Roche AG among others involved in the Immuno Oncology Clinical Trials Market, 2023 to 2033.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the Immuno Oncology Clinical Trials Market, 2023 to 2033, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview

• 1.1 Objectives of the Study
• 1.2 Introduction to Immuno Oncology Clinical Trials Market
• 1.3 What This Report Delivers
• 1.4 Why You Should Read This Report
• 1.5 Key Questions Answered by This Analytical Report
• 1.6 Who is This Report for?
• 1.7 Methodology
  • 1.7.1 Market Definitions
  • 1.7.2 Market Evaluation & Forecasting Methodology
  • 1.7.3 Data Validation
    • 1.7.3.1 Primary Research
    • 1.7.3.2 Secondary Research
• 1.8 Frequently Asked Questions (FAQs)
• 1.9 Associated Reports
• 1.10 About

2 Executive Summary

3 Market Overview

• 3.1 Key Findings
• 3.2 Market Dynamics
  • 3.2.1 Market Driving Factors
    • 3.2.1.1 Increase in Cancer Cases Has Compelled Biotech and Pharmaceutical Companies to Conduct More Clinical Immuno Oncology Tests
    • 3.2.1.2 Increasing Regulatory Approval for Immuno Oncology Drug
    • 3.2.1.3 Greater Investment in Healthcare R&D
  • 3.2.2 Market Restraining Factors
    • 3.2.2.1 Serious Issues and Substantial Medical Costs
    • 3.2.2.2 Regulatory Challenges
    • 3.2.2.3 Lack of Diversity
  • 3.2.3 Market Opportunities
    • 3.2.3.1 Potential for Partnership and Collaborations Offering Lucrative Opportunity
    • 3.2.3.2 Growing Number of Immuno Oncology Medication Clinical Studies
• 3.3 Porter's Five Forces Analysis
• 3.4 PEST Analysis
• 3.5 COVID-19 Impact Analysis

4 Immuno Oncology Clinical Trials Market Analysis by Phase

• 4.1 Key Findings
• 4.2 Phase Segment: Market Attractiveness Index
• 4.3 Immuno Oncology Clinical Trials Market Size Estimation and Forecast by Phase
• 4.4 Phase I
  • 4.4.1 Market Size by Region, 2023-2033 (US$ Million)
  • 4.4.2 Market Share by Region, 2023 & 2033 (%)
• 4.5 Phase II
  • 4.5.1 Market Size by Region, 2023-2033 (US$ Million)
  • 4.5.2 Market Share by Region, 2023 & 2033 (%)
• 4.6 Phase III
  • 4.6.1 Market Size by Region, 2023-2033 (US$ Million)
  • 4.6.2 Market Share by Region, 2023 & 2033 (%)
• 4.7 Phase IV
  • 4.7.1 Market Size by Region, 2023-2033 (US$ Million)
  • 4.7.2 Market Share by Region, 2023 & 2033 (%)

5 Immuno Oncology Clinical Trials Market Analysis by Design

• 5.1 Key Findings
• 5.2 Design Segment: Market Attractiveness Index
• 5.3 Immuno Oncology Clinical Trials Market Size Estimation and Forecast by Design
• 5.4 Interventional Trials
  • 5.4.1 Market Size by Region, 2023-2033 (US$ Million)
  • 5.4.2 Market Share by Region, 2023 & 2033 (%)
• 5.5 Observational Trials
  • 5.5.1 Market Size by Region, 2023-2033 (US$ Million)
  • 5.5.2 Market Share by Region, 2023 & 2033 (%)
• 5.6 Expanded Access Trials
  • 5.6.1 Market Size by Region, 2023-2033 (US$ Million)
  • 5.6.2 Market Share by Region, 2023 & 2033 (%)

6 Immuno Oncology Clinical Trials Market Analysis by Indication

• 6.1 Key Findings
• 6.2 Indication Segment: Market Attractiveness Index
• 6.3 Immuno Oncology Clinical Trials Market Size Estimation and Forecast by Indication
• 6.4 Solid Tumours
  • 6.4.1 Market Size by Region, 2023-2033 (US$ Million)
  • 6.4.2 Market Share by Region, 2023 & 2033 (%)
• 6.5 Hematological Cancer
  • 6.5.1 Market Size by Region, 2023-2033 (US$ Million)
  • 6.5.2 Market Share by Region, 2023 & 2033 (%)

7 Immuno Oncology Clinical Trials Market Analysis by Region

• 7.1 Key Findings
• 7.2 Regional Market Size Estimation and Forecast

8 North America Immuno Oncology Clinical Trials Market Analysis

• 8.1 Key Findings
• 8.2 North America Immuno Oncology Clinical Trials Market Attractiveness Index
• 8.3 North America Immuno Oncology Clinical Trials Market by Country, 2023, 2028 & 2033 (US$ Million)
• 8.4 North America Immuno Oncology Clinical Trials Market Size Estimation and Forecast by Country
• 8.5 North America Immuno Oncology Clinical Trials Market Size Estimation and Forecast by Phase
• 8.6 North America Immuno Oncology Clinical Trials Market Size Estimation and Forecast by Design
• 8.7 North America Immuno Oncology Clinical Trials Market Size Estimation and Forecast by Indication
• 8.8 U.S. Immuno Oncology Clinical Trials Market Analysis
• 8.9 Canada Immuno Oncology Clinical Trials Market Analysis

9 Europe Immuno Oncology Clinical Trials Market Analysis

• 9.1 Key Findings
• 9.2 Europe Immuno Oncology Clinical Trials Market Attractiveness Index
• 9.3 Europe Immuno Oncology Clinical Trials Market by Country, 2023, 2028 & 2033 (US$ Million)
• 9.4 Europe Immuno Oncology Clinical Trials Market Size Estimation and Forecast by Country
• 9.5 Europe Immuno Oncology Clinical Trials Market Size Estimation and Forecast by Phase
• 9.6 Europe Immuno Oncology Clinical Trials Market Size Estimation and Forecast by Design
• 9.7 Europe Immuno Oncology Clinical Trials Market Size Estimation and Forecast by Indication
• 9.8 Germany Immuno Oncology Clinical Trials Market Analysis
• 9.9 UK Immuno Oncology Clinical Trials Market Analysis
• 9.10 France Immuno Oncology Clinical Trials Market Analysis
• 9.11 Italy Immuno Oncology Clinical Trials Market Analysis
• 9.12 Spain Immuno Oncology Clinical Trials Market Analysis
• 9.13 Rest of Europe Immuno Oncology Clinical Trials Market Analysis

10 Asia Pacific Immuno Oncology Clinical Trials Market Analysis

• 10.1 Key Findings
• 10.2 Asia Pacific Immuno Oncology Clinical Trials Market Attractiveness Index
• 10.3 Asia Pacific Immuno Oncology Clinical Trials Market by Country, 2023, 2028 & 2033 (US$ Million)
• 10.4 Asia Pacific Immuno Oncology Clinical Trials Market Size Estimation and Forecast by Country
• 10.5 Asia Pacific Immuno Oncology Clinical Trials Market Size Estimation and Forecast by Phase
• 10.6 Asia Pacific Immuno Oncology Clinical Trials Market Size Estimation and Forecast by Design
• 10.7 Asia Pacific Immuno Oncology Clinical Trials Market Size Estimation and Forecast by Indication
• 10.8 China Immuno Oncology Clinical Trials Market Analysis
• 10.9 Japan Immuno Oncology Clinical Trials Market Analysis
• 10.10 India Immuno Oncology Clinical Trials Market Analysis
• 10.11 Australia Immuno Oncology Clinical Trials Market Analysis
• 10.12 South Korea Immuno Oncology Clinical Trials Market Analysis
• 10.13 Rest of Asia Pacific Immuno Oncology Clinical Trials Market Analysis

11 Latin America Immuno Oncology Clinical Trials Market Analysis

• 11.1 Key Findings
• 11.2 Latin America Immuno Oncology Clinical Trials Market Attractiveness Index
• 11.3 Latin America Immuno Oncology Clinical Trials Market by Country, 2023, 2028 & 2033 (US$ Million)
• 11.4 Latin America Immuno Oncology Clinical Trials Market Size Estimation and Forecast by Country
• 11.5 Latin America Immuno Oncology Clinical Trials Market Size Estimation and Forecast by Phase
• 11.6 Latin America Immuno Oncology Clinical Trials Market Size Estimation and Forecast by Design
• 11.7 Latin America Immuno Oncology Clinical Trials Market Size Estimation and Forecast by Indication
• 11.8 Brazil Immuno Oncology Clinical Trials Market Analysis
• 11.9 Mexico Immuno Oncology Clinical Trials Market Analysis
• 11.10 Rest of Latin America Immuno Oncology Clinical Trials Market Analysis

12 MEA Immuno Oncology Clinical Trials Market Analysis

• 12.1 Key Findings
• 12.2 MEA Immuno Oncology Clinical Trials Market Attractiveness Index
• 12.3 MEA Immuno Oncology Clinical Trials Market by Country, 2023, 2028 & 2033 (US$ Million)
• 12.4 MEA Immuno Oncology Clinical Trials Market Size Estimation and Forecast by Country
• 12.5 MEA Immuno Oncology Clinical Trials Market Size Estimation and Forecast by Phase
• 12.6 MEA Immuno Oncology Clinical Trials Market Size Estimation and Forecast by Design
• 12.7 MEA Immuno Oncology Clinical Trials Market Size Estimation and Forecast by Indication
• 12.8 South Africa Immuno Oncology Clinical Trials Market Analysis
• 12.9 GCC Immuno Oncology Clinical Trials Market Analysis
• 12.10 Rest of MEA Immuno Oncology Clinical Trials Market Analysis

13 Company Profiles

• 13.1 Competitive Landscape
• 13.2 Strategic Outlook
• 13.3 Merck & Co., Inc.
  • 13.3.1 Company Snapshot
  • 13.3.2 Company Overview
  • 13.3.3 Financial Analysis
    • 13.3.3.1 Net Revenue, 2017-2022
    • 13.3.3.2 R&D, 2017-2022
    • 13.3.3.3 Regional Market Shares, 2022
  • 13.3.4 Product Benchmarking
  • 13.3.5 Strategic Outlook
• 13.4 Bristol-Myers Squibb Company
  • 13.4.1 Company Snapshot
  • 13.4.2 Company Overview
  • 13.4.3 Financial Analysis
    • 13.4.3.1 Net Revenue, 2017-2022
    • 13.4.3.2 R&D, 2017-2022
    • 13.4.3.3 Regional Market Shares, 2022
  • 13.4.4 Product Benchmarking
  • 13.4.5 Strategic Outlook
• 13.5 Medpace, Inc.
  • 13.5.1 Company Snapshot
  • 13.5.2 Company Overview
  • 13.5.3 Financial Analysis
    • 13.5.3.1 Net Revenue, 2017-2022
  • 13.5.4 Product Benchmarking
  • 13.5.5 Strategic Outlook
• 13.6 Novartis AG
  • 13.6.1 Company Snapshot
  • 13.6.2 Company Overview
  • 13.6.3 Financial Analysis
    • 13.6.3.1 Net Revenue, 2017-2022
    • 13.6.3.2 R&D, 2017-2022
    • 13.6.3.3 Regional Market Shares, 2022
  • 13.6.4 Product Benchmarking
  • 13.6.5 Strategic Outlook
• 13.7 AstraZeneca plc
  • 13.7.1 Company Snapshot
  • 13.7.2 Company Overview
  • 13.7.3 Financial Analysis
    • 13.7.3.1 Net Revenue, 2017-2022
    • 13.7.3.2 R&D, 2017-2022
    • 13.7.3.3 Regional Market Shares, 2022
  • 13.7.4 Product Benchmarking
• 13.8 BioNTech SE
  • 13.8.1 Company Snapshot
  • 13.8.2 Company Overview
  • 13.8.3 Financial Analysis
    • 13.8.3.1 Net Revenue, 2017-2022
    • 13.8.3.2 R&D, 2017-2022
  • 13.8.4 Product Benchmarking
  • 13.8.5 Strategic Outlook
• 13.9 Exscientia plc
  • 13.9.1 Company Snapshot
  • 13.9.2 Company Overview
  • 13.9.3 Financial Analysis
    • 13.9.3.1 Net Revenue, 2020-2022
    • 13.9.3.2 R&D, 2020-2022
    • 13.9.3.3 Regional Market Shares, 2022
  • 13.9.4 Product Benchmarking
  • 13.9.5 Strategic Outlook
• 13.10 F. Hoffmann-La Roche AG
  • 13.10.1 Company Snapshot
  • 13.10.2 Company Overview
  • 13.10.3 Financial Analysis
    • 13.10.3.1 Net Revenue, 2017-2022
    • 13.10.3.2 R&D, 2017-2022
    • 13.10.3.3 Regional Market Shares, 2022
  • 13.10.4 Product Benchmarking
  • 13.10.5 Strategic Outlook
• 13.11 Pfizer Inc.
  • 13.11.1 Company Snapshot
  • 13.11.2 Company Overview
  • 13.11.3 Financial Analysis
    • 13.11.3.1 Net Revenue, 2017-2022
    • 13.11.3.2 R&D, 2017-2022
    • 13.11.3.3 Regional Market Shares, 2022
  • 13.11.4 Product Benchmarking
  • 13.11.5 Strategic Outlook
• 13.12 Syneos Health
  • 13.12.1 Company Snapshot
  • 13.12.2 Company Overview
  • 13.12.3 Financial Analysis
    • 13.12.3.1 Net Revenue, 2017-2022
    • 13.12.3.2 Regional Market Shares, 2021
  • 13.12.4 Product Benchmarking
  • 13.12.5 Strategic Outlook
• 13.13 IO Biotech, Inc.
  • 13.13.1 Company Snapshot
  • 13.13.2 Company Overview
  • 13.13.3 Product Benchmarking
  • 13.13.4 Strategic Outlook
• 13.14 ICON plc
  • 13.14.1 Company Snapshot
  • 13.14.2 Company Overview
  • 13.14.3 Financial Analysis
    • 13.14.3.1 Net Revenue, 2017-2022
    • 13.14.3.2 Regional Market Shares, 2022
  • 13.14.4 Product Benchmarking
• 13.15 IQVIA Inc.
  • 13.15.1 Company Snapshot
  • 13.15.2 Company Overview
  • 13.15.3 Financial Analysis
    • 13.15.3.1 Net Revenue, 2017-2022
    • 13.15.3.2 R&D, 2017-2022
    • 13.15.3.3 Regional Market Shares, 2022
  • 13.15.4 Product Benchmarking

14 Conclusion and Recommendations

• 14.1 Concluding Remarks from
• 14.2 Recommendations for Market Players